This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Johnson & Johnson (JNJ)

NYSE: Health Care

$101.15 +0.02 | 0.02%
05/28/15 - 4:00:00 PM ET
  • Prev Close: 101.13
  • Day's Open: 101.01
  • Volume: 5.69M
  • Avg Vol: 7.80M
  • Shares Outstanding: 2.77B
  • Mkt Cap: 279.58B
  • Div: $0.75
  • Div Yield: 3.00%
  • P/E: 18.04
  • EPS: 5.80
JNJ Day's Range
$100.81
$101.70
JNJ 52 Week Range
$95.10
$109.49
JNJ Business Summary
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.View JNJ key stats
Johnson & Johnson - JNJ - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Johnson & Johnson as a Buy with a ratings score of A-.
Report Snippet: We rate JOHNSON & JOHNSON (JNJ) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income.
Rating: 4.33 out of 5, 'A-' Buy.
You can view the full analysis from the report here:
JNJ Rating Report
JNJ Earnings Transcripts
  • Johnson And Johnson (JNJ) Earnings Report: Q1 2015 Conference Call Transcript
    TheStreet | 04/14/15 - 01:59 PM EDT
  • Johnson & Johnson (JNJ) Earnings Report: Q4 2014 Conference Call Transcript
    TheStreet | 01/20/15 - 02:47 PM EST
  • JOHNSON & JOHNSON (JNJ) Earnings Report: Q3 2014 Conference Call Transcript
    TheStreet | 10/14/14 - 11:50 AM EDT
JNJ Performance as of Prev. Close
YTD
-3.29%
3-Mo
-1.35%
1-Yr
0.32%
3-Yr
61.78%
JNJ EPS Performance
1-Yr Ago
5.80
2-Yrs Ago
4.92
3-Yrs Ago
3.94
JNJ Percentage in these ETFs
3.150%
1.890%
1.310%
0.200%
0.126%
JNJ News

JNJ Johnson & Johnson

Analysts Ratings for JNJ

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 6 6 6 6
Moderate Buy 2 3 3 3
Hold 7 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET JNJ ANALYST REPORT

Brokerage Partners

JNJ Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs